Annual Reports in Medicinal Chemistry: v. 29

Annual Reports in Medicinal Chemistry: v. 29

Volume editor 

List price: US$70.00

Currently unavailable

Add to wishlist

AbeBooks may have this title (opens in new window).

Try AbeBooks

Description

This serial continues to combine regular updates of significant areas of research in medicinal chemistry with emerging areas of biological science destined to impact the discovery and development of new medicinal agents.
show more

Product details

  • Paperback | 472 pages
  • 171 x 248 x 20mm | 685g
  • Academic Press Inc
  • San Diego, United States
  • English
  • indices
  • 0120405296
  • 9780120405299

Review quote

Praise for the Series "This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development." - ENZYMOLOGIA "This book is strongly recommended for researchers, teachers, students, administrators o in short, anyone whose interests impinge on medicinal chemistry. In view of the work's documented reference value, it is a must for inclusion in the scientist's personal library." - JOURNAL OF MEDICINAL CHEMISTRY "All topics are coveed in sufficient depth, with extensie references, to allow either the specialist or the novice to be informed of the latest developments in a particular area of medicial chemistry." - NORMAN GILMAN, HOFFMANN-LA ROCHE, INC., JOURNAL OF PHARMACEUTICAL SCIENCES
show more

Table of contents

Part 1 CNS agents: third generation antidepressants; neuronal cell death; muscarinic agonists and antagonists; animal engineering in neurobiology; dopamine D3 and D4 receptor ligands and pharmacology; excitatory amino acid research. Part 2 Cardiovascular and pulmonary agents: endothelin receptor antagonists; treatment of asthma and allergy; nitric oxide synthase; thrombolytic agents; antithrombotic and anti-inflammatory agents. Part 3 Chemotherapeutic agents: antibacterial agents; HIV reverse transcriptase inhibitors; HIV protease inhibitors; ras oncogene. Part 4 Immunology, endocrinology and metabolic diseases: non-immunophilin-related immunosuppressants; phosphodiesterase inhibitors as antiasthmatic agents; human leukocyte elastase inhibitors; interleukin-1; cell adhesion and carbohydrates; control of androgen action. Part 5 Topics in biology: transcription factor NF-kB; translational control of gene expression; protein kinases and photophatases; transgenic and gene targeting technology; osteoporosis. Part 6 Topics in drug design and discovery: adenylate cyclase subtypes; advances in antisense technology; prediction of human drug metabolism; humanized monoclonal antibodies; ethnobotany. Part 7 Trends and perspectives: to market, to market - 1993; appendices.
show more